J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal Article
Salvage therapy for patients with lymphoma.
TL;DR: The likelihood of attaining a complete remission is greatest with primary therapy and declines with each relapse, so it is tremendously important that patients with lymphoma be managed optimally at the time of their initial treatment.
Journal ArticleDOI
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma
Matthew A. Lunning,Julie M. Vose,Marshall T. Schreeder,Nathan Fowler,Loretta J. Nastoupil,Tanya Siddiqi,Susan Blumel,Emily K. Pauli,Kathy Cutter,Warner H Tse,Hari P. Miskin,Peter Sportelli,Michael S. Weiss,Swaroop Vakkalanka,Srikant Viswanadha,Susan O'Brien +15 more
TL;DR: This Phase 1 trial evaluates safety and efficacy of the combination of a glycoengineered anti-CD20 (UTX) and a PI3Kδ inhibitor (TGR-1202) in pts with heavily pre-treated relapsed or refractory CLL and NHL and shows 80% displayed a reduction in tumor burden at first efficacy assessment, despite pts exhibiting a number of high-risk characteristics.
Journal ArticleDOI
High dose cyclophosphamide, etoposide and carmustine and peripheral stem cell transplantation for patients with relapsed hodgkin disease and bone marrow abnormalities
Journal ArticleDOI
Update on T-cell lymphoma
TL;DR: Evaluated the various subtypes of lymphoma and other disorders found among cases from 22 sites in North America, Europe and Asia and found the most common subtype identified was PTCL, not otherwise specified (NOS) (25.8%).
Journal ArticleDOI
Detection of Tumor Contamination of Peripheral Stem Cells in Patients with Lymphoma Using Cell Culture and Polymerase Chain Reaction Technology
TL;DR: The sensitivity of tumor detection and the predictive value for patient survival of the PCR-based and culture-based assays are compared to determine whether minimal tumor contamination of an autologous graft is clinically significant and, if so, the assay(s) that should be employed.